Here, we describe an exploratory biomarker analysis using next-generation sequencing (NGS) of pretreatment tumor tissues to evaluate the genomic and transcriptomic profiles associated with the response to the eribulin and nivolumab combination in patients with human epidermal growth factor receptor-2 (HER-2) negative breast cancer. This evidence concerns the gene ERBB2 and neoplasm.